Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Macrophage senescence
- Molecular classification
- Other (Cellular state/phenotype)
01
Overview
Macrophage senescence describes a state in which macrophages undergo durable cell cycle arrest accompanied by functional and molecular changes including impaired metabolism, increased pro-inflammatory cytokine production (SASP), altered phagocytosis, and reduced autophagy. Senescent macrophages accumulate with aging, chronic stress, and exposure to damaging agents, contributing to chronic inflammation and age-related diseases. While removal or modulation of senescent macrophages is considered a potential therapeutic intervention, "macrophage senescence" itself does not represent a discrete molecular entity or drug target, but rather a complex, dynamic cellular phenotype implicated in both pathology and tissue remodeling.
- Other names
- Senescent macrophageAging macrophage
02
Mechanism of action
Clearance of senescent macrophages; Inhibition of senescence-associated secretory phenotype (SASP); Promotion of autophagy; Modulation of inflammatory mediator production; Modulation of mitochondrial pathways
03
Biological functions
Immune response (altered/inflammatory)Cell cycle arrestMetabolic regulation/dysfunctionAltered phagocytosisAntigen presentationAutophagy impairment
04
Disease associations
CancerInflammationNeurodegenerative diseaseCardiovascular diseaseInfectionAge-related diseasesFibrosis
05
Safety considerations
Non-specific targeting: risk of impairing beneficial macrophage functions (clearance, tissue repair)Potential for immune suppressionIncomplete elimination: risk of chronic inflammation if senescent cells persistBiomarker specificity and off-target effects of senotherapeutics remain challenges
06
Interacting drugs
Senolytics (experimental; compounds that target and eliminate senescent cells)
2 more in the full profile.
07
Biomarkers
Increased senescence-associated β-galactosidase (SA-β-Gal) activity (though unreliable in vivo for macrophages)Expression of cell cycle inhibitors (e.g., p16^INK4a^, p21^CIP1^)Increased proinflammatory cytokines: IL-6, IL-1β, TNF-α (components of SASP)Downregulation of autophagy-related genesMitochondrial dysfunction markers
Beyond the preview
Go deeper on Macrophage senescence.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Macrophage senescence.